Review: Current and new generation pneumococcal vaccines

Journal of Infection

Volumn 69, Issue 4, 2014, Pages 309-325

  Feldman, Charles ^a,b   Anderson, Ronald ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Pneumococcal choline binding protein A; Pneumococcal conjugate vaccines; Pneumococcal polysaccharide vaccines; Pneumococcal surface protein A; Pneumococcal surface protein C; Pneumolysin; Polyhistidine triad proteins; Recombinant protein vaccines; Streptococcus pneumoniae; Whole cell vaccines

Indexed keywords

BACTERIAL PROTEIN; CHOLINE BINDING PROTEIN E; ENOLASE; IMMUNOGLOBULIN A1; LACTOFERRIN; NEURAMINIDASE A; NEURAMINIDASE B; PLASMIN AND FIBRONECTIN BINDING PROTEIN; PNEUMOCOCCAL ADHERENCE A; PNEUMOCOCCAL ADHERENCE B; PNEUMOCOCCAL CHOLINE BINDING PROTEIN A; PNEUMOCOCCAL PILI PROTEIN; PNEUMOCOCCAL SERINE RICH REPEAT PROTEIN; PNEUMOCOCCAL SURFACE ADHESIN A; PNEUMOCOCCAL SURFACE PROTEIN C; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; POLYHISTIDINE; POLYHISTIDINE TRIAD PROTEIN; REACTIVE OXYGEN METABOLITE; SIALIDASE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; RECOMBINANT VACCINE;

BACTERIAL VIRULENCE; CELL MIGRATION; COMPLEMENT ACTIVATION; DRUG EFFICACY; HOST RESISTANCE; HUMAN; INFECTION PREVENTION; INFECTION RISK; MORTALITY; NEUTROPHIL; NONHUMAN; PNEUMOCOCCAL INFECTION; PRODUCT DEVELOPMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; VACCINE PRODUCTION; CHEMISTRY; IMMUNOLOGY; PNEUMOCOCCAL INFECTIONS;

ANTIGENS, BACTERIAL; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, SYNTHETIC;

EID: 84908897502     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.06.006     Document Type: Review

References (185)

1. McDaniel L.S., Swiatlo E. Pneumococcal disease. Pathogenesis, treatment, and prevention. Infect Dis Clin Pract 2004, 12:93-98.
2. Steel H.C., Cockeran R., Anderson R., Feldman C. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm 2013, 2013:490346.
3. Weinberger D.M., Trzciński K., Lu Y.-J., Bogaert D., Brandes A., Galagan J., et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 2009, 5:e1000476.
4. Macleod C.M., Hodges R.G., Heidelberger M., Bernhard W.G. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945, 82:445-465.
5. Ludwig E., Bonnani P., Rohde G., Sayiner A., Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012, 21:57-65.
6. Blasi F., Mantero M., Santus P., Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect 2012, 18:7-14.
7. Said M.A., Johnson H.L., Nonyane B.A.S., Deloria-Knoll M., O'Brien K.L. AGEDD Adult Pneumococcal Burden Study Team. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013, 8:e60273.
8. Drijkoningen J.J.C., Rohde G.G.U. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 2014, 20:45-51.
9. Villa-Corcoles A., Ochoa-Gondar O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging 2013, 30:263-276.
10. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009, 30:189-209.
11. Sanz Herrero F., Blanquer Olivas J. Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med 2012, 33:220-231.
12. Rozenbaum M.H., Pechlivanoglou P., van der Werf T.S., Lo-Ten-Foe J.R., Postma M.J., Hak E. The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis 2013, 32:305-316.
13. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122:130-141.
14. Song J.H., Thamlikitkul V., Hsueh P.R. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents 2011, 38:108-117.
15. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012, 67:71-79.
16. Huang S.S., Johnson K.M., Ray G.T., Wroe P., Lieu T.A., Moore M.R., et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011, 29:3398-3412.
17. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294:2043-2051.
18. Lynch J.P., Zhanel G.G. Streptococcus penumoniae: does antimicrobial resistance matter?. Semin Respir Crit Care Med 2009, 30:210-238.
19. Liñares J., Ardanuy C., Pallares R., Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010, 16:402-410.
20. Chidiac C. Pneumococcal infections and adult with risk factors. Med Mal Infect 2012, 42:517-524.
21. Wroe P.C., Finkelstein J.A., Ray G.T., Linder J.A., Johnson K.M., Rifas-Shiman S., et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis 2012, 205:1589-1592.
22. Pneumococcal vaccination: who needs it? Vaccines and immunizations 2014, [last accessed 22 April 2014]. http://www.cdc.gov/vaccines/vpd-vac/pneumo/.
23. Naucler P., Darenberg J., Morfeldt E., Örtqvist A., Henriques Normark B. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013, 68:571-579.
24. Garnacho-Montero J., Garcia-Cabrera E., Diaz-Martin A., Lepe-Jiménez J.A., Iraurgi-Arcarazo P., Jiménez-Alvarez R., et al. Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: importance of early adequate treatment. Scand J Infect Dis 2010, 42:185-192.
25. Musher D.M. Pneumococcal vaccination in adults December 2013, UpToDate. http://www.uptodate.com.
26. Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults. Drugs 2012, 72:1243-1255.
27. Scott L.J., Sanford M. Pneumococcal polysaccharide conjugate vaccine (13- valent, adsorbed): a guide to its use in older adults. Drugs Aging 2012, 29:847-855.
28. Centers for Disease Control and Prevention (CDC) Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010, 59:1102-1106.
29. Centers for Disease Control and Prevention (CDC) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61:816-819.
30. Jackson L.A., Janoff E.N. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008, 47:1328-1338.
31. Pedersen R.H., Lohse N., Østergaard L., Søgaard O.S. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011, 12:323-333.
32. Fedson D.S., Nicolas-Spony L., Klemets P., van der Linden M., Marques A., Salleras L., et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011, 10:1143-1167.
33. Icardi G., Sticchi L., Bagnasco A., Iudici R., Durando P. Pneumococcal vaccination in adults: rationale, state of the art and perspectives. J Prev Med Hyg 2012, 53:78-84.
34. Musher D.M. How effective is vaccination in preventing pneumococcal disease?. Infect Dis Clin North Am 2013, 27:229-241.
35. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180:48-58.
36. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013, 1:CD000422.
37. Ochoa-Gondar O., Vila-Corcoles A., Rodriguez-Blanco T., Gomez-Bertomeu F., Figuerola-Massana E., Raga-Luria X., et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population ages ≥60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014, 58:909-917.
38. Wiemken T.L., Carrico R.M., Klein S.L., Jonsson C.B., Peyrani P., Kelley R.R., et al. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine 2014, 32:2198-2203.
39. Törling J., Hedlund J., Konradsen H.B., Örtqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003, 22:96-103.
40. Brynjolfsson S.F., Henneken M., Bjarnarson S.P., Mori E., Del Giudice G., Jonsdottir I. Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells. J Infect Dis 2012, 205:422-430.
41. Schenkein J.G., Park S., Nahm M.H. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 2008, 26:5521-5526.
42. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
43. Griffin M.R., Zhu Y., Moore M.R., Whitney C.G., Grijalva C.G. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013, 369:155-163.
44. Paradiso P.R. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis 2012, 55:259-264.
45. Jackson L.A., Gurtman A., van Cleeff M., Jansen K.U., Jayawardene D., Devlin C., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults. Vaccine 2013, 31:3577-3584.
46. Jackson L.A., Gurtman A., van Cleeff M., Frenck R.W., Treanor J., Jansen K.U., et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013, 31:3594-3602.
47. Greenberg R.N., Gurtman A., Frenck R.W., Strout C., Jansen K.U., Trammel J., et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 2014, 32:2364-2374.
48. Jackson L.A., Gurtman A., Rice K., Pauksens K., Greenberg R.N., Jones T.R., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013, 31:3585-3593.
49. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010, 362:812-822.
50. Hak E., Grobbee D.E., Sanders E.A.M., Verheij T.J.M., Bolkenbaas M., Huijts S.M., et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008, 66:378-383.
51. [last accessed 9 May 2014]. http://www.empr.com/detailed-data-from-prevnar-13-capita-study-released/article/337871/.
52. Smith K.J., Wateska A.R., Nowalk M.P., Raymund M., Nuorti J.P., Zimmerman R.K. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012, 307:804-812.
53. Smith K.J., Nowalk M.P., Raymund M., Zimmerman R.K. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine 2013, 31:3950-3956.
54. Smith K.J., Wateska A.R., Nowalk M.P., Raymund M., Lee B.Y., Zimmerman R.K. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J Prev Med 2013, 44:373-381.
55. Weycker D., Sato R., Strutton D., Edelsberg J., Atwood M., Jackson L.A. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults ages >50 years. Vaccine 2012, 30:5437-5444.
56. Weil-Olivier C., Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults?. Vaccine 2014, 32:2022-2026.
57. Van de Vooren K., Duranti S., Curto A., Garattini L. Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics 2014, 32:29-45.
58. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196:1346-1354.
59. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-1973.
60. Feikin D.R., Kagucia E.W., Loo J.D., Link-Gelles R., Puhan M.A., Cherian T., et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013, 10:e1001517.
61. Cadeddu C., De Waure C., Gualano M.R., Di Nardo F., Ricciardi W. 23-Valent pneumococcal polysaccharide vaccine (PPV23) for the prevention of invasive pneumococcal diseases (IPDs) in the elderly: is it really effective?. J Prev Med Hyg 2012, 53:101-103.
62. Leggat D.J., Thompson R.S., Khaskhely N.M., Iyer A.S., Westerink M.A. The immune response to pneumococcal polysaccharides 14 and 23F among elderly individuals consists predominantly of switched memory B cells. J Infect Dis 2013, 208:101-108.
63. Falup-Pecurariu O. Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines. Biomed J 2012, 35:450-456.
64. Postma D.F., van Werkhoven C.H., Huijts S.M., Bolkenbaas M., Oosterheert J.J., Bonten M.J.M. New trends in the prevention and management of community-acquired pneumonia. Neth J Med 2012, 70:337-348.
65. Miyaji E.N., Oliveira M.L., Carvalho E., Ho P.L. Serotype-independent pneumococcal vaccines. Cell Mol Life Sci 2013, 70:3303-3326.
66. Nunes M.C., Madhi S.A. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother 2012, 8:161-173.
67. Biesbroek G., Wang X., Keijser B.J., Eijkemans R.M., Trzciński K., Rots N.Y., et al. Seven-valent pneumococcal conjugate vaccine and nasopharyngeal microbiota in healthy children. Emerg Infect Dis 2014, 20:201-210.
68. Moffitt K.L., Gierahn T.M., Lu Y.J., Gouveia P., Alderson M., Flechtner J.B., et al. T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011, 9:158-165.
69. Malley R., Anderson P.W. Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc Natl Acad Sci U S A 2012, 109:3623-3627.
70. Singh R., Gupta P., Sharma P.K., Ades E.W., Hollingshead S.K., Singh S., et al. Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology 2014, 141:514-530.
71. Ditse Z., Adrian P.V., Kuwanda L., Madhi S.A. Association of Streptococcus pneumoniae common protein antigen (CPA) antibodies and pneumococcal nasopharyngeal colonization in HIV-infected and HIV-uninfected African children. Vaccine 2013, 31:4421-4427.
72. Ginsburg A.S., Alderson M.R. New conjugate vaccines for the prevention of pneumococcal disease in developing countries. Drugs Today 2011, 47:207-214.
73. Dagan R., Givon-Lavi N., Greenberg D., Fritzell B., Siegrist C.A. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010, 201:1570-1579.
74. Väkeväinen M., Soininen A., Lucero M., Nohynek H., Auranen K., Mäkelä P.H., et al. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J Pediatr 2010, 157:778-783.
75. Madhi S.A., Violari A., Klugman K.P., Lin G., McIntyre J.A., von Gottberg A., et al. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization. Vaccine 2011, 29:6994-7001.
76. Temime L., Boelle P.Y., Opatowski L., Guillemot D. Impact of capsular switch on invasive pneumococcal disease incidence in a vaccinated population. PLoS One 2008, 3:e3244.
77. Wyres K.L., Lambertsen L.M., Croucher N.J., McGee L., von Gottberg A., Liñares J., et al. Pneumococcal capsular switching: a historical perspective. J Infect Dis 2013, 207:439-449.
78. Skinner J.M., Indwawati L., Cannon J., Blue J., Winters M., MacNair J., et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011, 29:8870-8876.
79. Dockrell D.H., Whyte M.K., Mitchell T.J. Pneumococcal pneumonia: mechanisms of infection and resolution. Chest 2012, 142:482-491.
80. Vernatter J., Pirofski L. Current concepts in host-microbe interaction leading to pneumococcal pneumonia. Curr Opin Infect Dis 2013, 26:277-283.
81. Sanchez C.J., Hinojosa C.A., Shivshankar P., Hyams C., Camberlein E., Brown J.S., et al. Changes in serotype alter the surface exposure of pneumococcal adhesins and impact virulence. PLoS One 2011, 6:e26587.
82. Anderton J.M., Rajam G., Romero-Steiner S., Summer S., Kowalczyk A.P., Carlone G.M., et al. E-cadherin is a receptor for the common protein pneumococcal surface adhesin A (PsaA) of Streptococcus pneumoniae. Microb Pathog 2007, 42:225-236.
83. Zhang J.R., Mostov K.E., Lamm M.E., Nanno M., Shimida S., Ohwaki M., et al. The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell 2000, 102:827-837.
84. Quin L.R., Onwubiko C., Moore Q.C., Mills M.F., McDaniel L.S., Carmicle S. Factor H binding to PspC of Streptococcus pneumoniae increases adherence to human cell lines invitro and enhances invasion of mouse lungs invivo. Infect Immun 2007, 75:4082-4087.
85. Agarwal V., Hammerschmidt S. Cdc42 and the phosphatidylinositol 3-kinase-Akt pathway are essential for PspC-mediated internalization of pneumococci by respiratory epithelial cells. J Biol Chem 2009, 284:19427-19436.
86. Cao J., Gong Y., Cai B., Feng W., Wu Y., Li L., et al. Modulation of human bronchial epithelial cells by pneumococcal choline binding protein A. Hum Immunol 2011, 72:37-46.
87. Meri T., Amdahl H., Lehtinen M.J., Hyvärinen S., McDowell J.V., Bhattacharjee A., et al. Microbes bind complement inhibitor factor H via a common site. PLoS Pathog 2013, 9:e1003308.
88. Józsi M., Oppermann M., Lambris J.D., Zipfel P.F. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol 2007, 44:2697-2706.
89. Voss S., Hallström T., Saleh M., Burchhardt G., Pribyl T., Singh B., et al. The choline-binding protein PspC of Streptococcus pneumoniae interacts with the C-terminal heparin-binding domain of vitronectin. J Biol Chem 2013, 288:15614-15627.
90. Salazar-Pelaez L.M., Abraham T., Pare P.D., Seow C.Y., Herrera Torres A.M. Confocal imaging and quantitative analysis of vitronectin expression by submucosal glands and surface epithelium of large airways. Am J Respir Crit Care Med 2013, 187(Meeting Abstracts). A56:A1834.
91. Attali C., Frolet C., Durmort C., Offant J., Vernet T., Di Guilmi A.M. Streptococcus pneumoniae choline-binding protein E interaction with plasminogen/plasmin stimulates migration across the extracellular matrix. Infect Immun 2008, 76:466-476.
92. Miles L.A., Andronicos N.M., Baik N., Parmer R.J. Cell-surface actin binds plasminogen and modulates neurotransmitter release from catecholaminergic cells. J Neurosci 2006, 26:13017-13024.
93. Bergmann S., Schoenen H., Hammerschmidt S. The interaction between bacterial enolase and plasminogen promotes adherence of Streptococcus pneumonia to epithelial and endothelial cells. Int J Med Microbiol 2013, 303:452-462.
94. Yamaguchi M., Terao Y., Mori Y., Hamada S., Kawabata S. PfbA, a novel plasmin- and fibronectin-binding protein of Streptococcus pneumoniae, contributes to fibronectin-dependent adhesion and antiphagocytosis. J Biol Chem 2008, 283:36272-36279.
95. Beulin D.S., Yamaguchi M., Kawabata S., Ponnuraj K. Crystal structure of PfbA, a surface adhesin of Streptococcus pneumoniae, provides hints into its interaction with fibronectin. Int J Biol Macromol 2014, 64:168-173.
96. Paterson G.K., Orihuela C.J. Pneumococcal microbial surface components recognizing adhesive matrix molecules targeting of the extracellular matrix. Mol Microbiol 2010, 77:1-5.
97. Kadioglu A., Brewin H., Härtel T., Brittan J.L., Klein M., Hammerschmidt S., et al. Pneumococcal protein PavA is important for nasopharyngeal carriage and development of sepsis. Mol Oral Microbiol 2010, 25:50-60.
98. Khan M.N., Pichichero M.E. Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans. Vaccine 2012, 30:2900-2907.
99. Plumptre C.D., Ogunniyi A.D., Paton J.C. Surface association of Pht proteins of Streptococcus pneumoniae. Infect Immun 2013, 81:3644-3651.
100. Shivshankar P., Sanchez C., Rose L.F., Orihuela C.J. The Streptococcus pneumoniae adhesin PsrP binds to keratin 10 on lung cells. Mol Microbiol 2009, 73:663-679.
101. Schulte T., Löfling J., Mikaelsson C., Kikhney A., Hentrich K., Diamante A., et al. The basic keratin 10-binding domain of the virulence-associated pneumococcal serine-rich protein PsrP adopts a novel MSCRAMM fold. Open Biol 2014, 4:130090.
102. Muñoz-Almagro C., Selva L., Sanchez C.J., Esteva C., de Sevilla M.F., Pallares R., et al. PsrP, a protective pneumococcal antigen, is highly prevalent in children with pneumonia and is strongly associated with clonal type. Clin Vaccine Immunol 2010, 17:1672-1678.
103. Khan M.N., Sharma S.K., Filkins L.M., Pichichero M.E. PcpA of Streptococcus pneumoniae mediates adherence to nasopharyngeal and lung epithelial cells and elicits functional antibodies in humans. Microbes Infect 2012, 14:1102-1110.
104. Nelson A.L., Ries J., Bagnoli F., Dahlberg S., Fälker S., Rounioja S., et al. RrgA is a pilus-associated adhesin in Streptococcus pneumoniae. Mol Microbiol 2007, 66:329-340.
105. Hilleringmann M., Giusti F., Baudner B.C., Masignani V., Covacci A., Rappuoli R., et al. Pneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg A. PLoS Pathog 2008, 4:e1000026.
106. Bagnoli F., Moschioni M., Donati C., Dimitrovska V., Ferlenghi I., Facciotti C., et al. A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol 2008, 190:5480-5492.
107. Barocchi M.A., Ries J., Zogaj X., Hemsley C., Albiger B., Kanth A., et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A 2006, 103:2857-2862.
108. Gianfaldoni C., Censini S., Hilleringmann M., Moschioni M., Facciotti C., Pansegrau W., et al. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun 2007, 75:1059-1062.
109. Moschioni M., De Angelis G., Harfouche C., Bizzarri E., Filippini S., Mori E., et al. Immunization with the RrgB321 fusion protein protects mice against both high and low pilus-expressing Streptococcus pneumoniae populations. Vaccine 2012, 30:1349-1356.
110. Kulohoma B.W., Gray K., Kamng'ona A., Cornick J., Bentley S.D., Heyderman R.S., et al. Piliation of invasive Streptococcus pneumoniae isolates in the era before pneumococcal conjugate vaccine introduction in Malawi. Clin Vaccine Immunol 2013, 20:1729-1735.
111. Laurenceau R., Péhau-Arnaudet G., Baconnais S., Gault J., Malosse C., Dujeancourt A., et al. A type IV pilus mediates DNA binding during natural transformation in Streptococcus pneumoniae. PLoS Pathog 2013, 9:e1003473.
112. Brittan J.L., Buckeridge T.J., Finn A., Kadioglu A., Jenkinson H.F. Pneumococcal neuraminidase A: an essential upper airway colonization factor for Streptococcus pneumoniae. Mol Oral Microbiol 2012, 27:270-283.
113. Niu S., Luo M., Tang J., Zhou H., Zhang Y., Min X., et al. Structural basis of the novel S. pneumoniae virulence factor, GHIP, a glycosyl hydrolase 25 participating in host-cell invasion. PLoS One 2013, 8:e68647.
114. Jedrzejas M.J. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev 2001, 65:187-207.
115. Muchnik L., Adawi A., Ohayon A., Dotan S., Malka I., Azriel S., et al. NADH oxidase functions as an adhesin in Streptococcus pneumoniae and elicits a protective immune response in mice. PLoS One 2013, 8:e61128.
116. Agarwal V., Kuchipudi A., Fulde M., Riesbeck K., Bergmann S., Blom A.M. Streptococcus pneumoniae endopeptidase O (PepO) is a multifunctional plasminogen- and fibronectin-binding protein, facilitating evasion of innate immunity and invasion of host cells. J Biol Chem 2013, 288:6849-6863.
117. Frolet C., Beniazza M., Roux L., Gallet B., Noirclerc-Savoye M., Vernet T., et al. New adhesin functions of surface-exposed pneumococcal proteins. BMC Microbiol 2010, 10:190.
118. Camilli R., Pettini E., Del Grosso M., Pozzi G., Pantosti A., Oggioni M.R. Zinc metalloproteinase genes in clinical isolates of Streptococcus pneumoniae: association of the full array with a clonal cluster comprising serotypes 8 and 11A. Microbiology 2006, 152:313-321.
119. Gong Y., Xu W., Cui Y., Zhang X., Yao R., Li D., et al. Immunization with a ZmpB-based protein vaccine could protect against pneumococcal diseases in mice. Infect Immun 2011, 79:867-878.
120. de Stoppelaar S.F., Bootsma H.J., Zomer A., Roelofs J.J., Hermans P.W., van 't Veer C., et al. Streptococcus pneumoniae serine protease HtrA, but not SFP or PrtA, is a major virulence factor in pneumonia. PLoS One 2013, 8:e80062.
121. Marriott H.M., Mitchell T.J., Dockrell D.H. Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med 2008, 8:497-509.
122. Mellroth P., Daniels R., Eberhardt A., Rönnlund D., Blom H., Widengren J., et al. LytA, major autolysin of Streptococcus pneumoniae, requires access to nascent peptidoglycan. J Biol Chem 2012, 287:11018-11029.
123. Price K.E., Greene N.G., Camilli A. Export requirements of pneumolysin in Streptococcus pneumoniae. J Bacteriol 2012, 194:3651-3660.
124. Price K.E., Camilli A. Pneumolysin localizes to the cell wall of Streptococcus pneumoniae. J Bacteriol 2009, 191:2163-2168.
125. Witzenrath M., Gutbier B., Hocke A.C., Schmeck B., Hippenstiel S., Berger K., et al. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med 2006, 34:1947-1954.
126. Hyams C., Trzcinski K., Camberlein E., Weinberger D.M., Chimalapati S., Noursadeghi M., et al. Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b. Infect Immun 2013, 81:354-363.
127. Suresh M.V., Singh S.K., Ferguson D.A., Agrawal A. Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol 2006, 176:4369-4374.
128. Mukerji R., Mirza S., Roche A.M., Widener R.W., Croney C.M., Rhee D.K., et al. Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol 2012, 189:5327-5335.
129. Ren B., Li J., Genschmer K., Hollingshead S.K., Briles D.E. The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci invitro. Clin Vaccine Immunol 2012, 19:1574-1582.
130. Dieudonné-Vatran A., Krentz S., Blom A.M., Meri S., Henriques-Normark B., Riesbeck K., et al. Clinical isolates of Streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion. J Immunol 2009, 182:7865-7877.
131. Agarwal V., Hammerschmidt S., Malm S., Bergmann S., Riesbeck K., Blom A.M. Enolase of Streptococcus pneumoniae binds human complement inhibitor C4b-binding protein and contributes to complement evasion. J Immunol 2012, 189:3575-3584.
132. Pericone C.D., Overweg K., Hermans P.W., Weiser J.N. Inhibitory and bactericidal effects of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper respiratory tract. Infect Immun 2000, 68:3990-3997.
133. Feldman C., Anderson R., Cockeran R., Mitchell T., Cole P., Wilson R. The effects of pneumolysin and hydrogen peroxide, alone and in combination, on human ciliated epithelium invitro. Respir Med 2002, 96:580-585.
134. Saleh M., Bartual S.G., Abdullah M.R., Jensch I., Asmat T.M., Petruschka L., et al. Molecular architecture of Streptococcus pneumoniae surface thioredoxin-fold lipoproteins crucial for extracellular oxidative stress resistance and maintenance of virulence. EMBO Mol Med 2013, 5:1852-1870.
135. Ibrahim Y.M., Kerr A.R., McCluskey J., Mitchell T.J. Role of HtrA in the virulence and competence of Streptococcus pneumoniae. Infect Immun 2004, 72:3584-3591.
136. Cao J., Zhang X., Gong Y., Zhang Y., Cui Y., Lai X., et al. Protection against pneumococcal infection elicited by immunization with multiple pneumococcal heat shock proteins. Vaccine 2013, 31:3564-3571.
137. Yamaguchi M., Terao Y., Mori-Yamaguchi Y., Domon H., Sakaue Y., Yagi T., et al. Streptococcus pneumoniae invades erythrocytes and utilizes them to evade human innate immunity. PLoS One 2013, 8:e77282.
138. Shaper M., Hollingshead S.K., Benjamin W.H., Briles D.E. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun 2004, 72:5031-5040.
139. Surewaard B.G., Trzciński K., Jacobino S.R., Hansen I.S., Vughs M.M., Sanders E.A., et al. Pneumococcal immune evasion: ZmpC inhibits neutrophil influx. Cell Microbiol 2013, 15:1753-1765.
140. Hahn S., Giaglis S., Chowdhury C.S., Hösli I., Hasler P. Modulation of neutrophil NETosis: interplay between infectious agents and underlying host physiology. Semin Immunopathol 2013, 35:439-453.
141. Mori Y., Yamaguchi M., Terao Y., Hamada S., Ooshima T., Kawabata S. α-Enolase of Streptococcus pneumoniae induces formation of neutrophil extracellular traps. J Biol Chem 2012, 287:10472-10481.
142. Short K.R., von Köckritz-Blickwede M., Langereis J.D., Chew K.Y., Job E.R., Armitage C.W., et al. Antibodies mediate formation of neutrophil extracellular traps in the middle ear and facilitate secondary pneumococcal otitis media. Infect Immun 2014, 82:364-370.
143. Narayana Moorthy A., Narasaraju T., Rai P., Perumalsamy R., Tan K.B., Wang S., et al. Invivo and invitro studies on the roles of neutrophil extracellular traps during secondary pneumococcal pneumonia after primary pulmonary influenza infection. Front Immunol 2013, 4:56.
144. Beiter K., Wartha F., Albiger B., Normark S., Zychlinsky A., Henriques-Normark B. An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr Biol 2006, 16:401-407.
145. Saffarzadeh M., Juenemann C., Queisser M.A., Lochnit G., Barreto G., Galuska S.P., et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 2012, 7:e32366.
146. Janoff E.N., Rubins J.B., Fasching C., Charboneau D., Rahkola J.T., Plaut A.G., et al. Pneumococcal IgA1 protease subverts specific protection by human IgA1. Mucosal Immunol 2014, 7:249-256.
147. Darrieux M., Goulart C., Briles D., Leite L.C. Current status and perspectives on protein-based pneumococcal vaccines. Crit Rev Microbiol 2013;Jul 29, [Epub ahead of print].
148. Auranen K., Rinta-Kokko H., Goldblatt D., Nohynek H., O'Brien K.L., Satzke C., et al. Design questions for Streptococcus pneumoniae vaccine trials with a colonisation endpoint. Vaccine 2013, 32:159-164.
149. Baril L., Dietemann J., Essevaz-Roulet M., Béniguel L., Coan P., Briles D.E., et al. Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults. Clin Exp Immunol 2006, 145:277-286.
150. Moreno A.T., Oliveira M.L., Ferreira D.M., Ho P.L., Darrieux M., Leite L.C., et al. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol 2010, 17:439-446.
151. Mureithi M.W., Finn A., Ota M.O., Zhang Q., Davenport V., Mitchell T.J., et al. T cell memory response to pneumococcal protein antigens in an area of high pneumococcal carriage and disease. J Infect Dis 2009, 200:783-793.
152. Khan M.N., Pichichero M.E. CD4 T cell memory and antibody responses directed against the pneumococcal histidine triad proteins PhtD and PhtE following nasopharyngeal colonization and immunization and their role in protection against pneumococcal colonization in mice. Infect Immun 2013, 81:3781-3792.
153. Frey S.E., Lottenbach K.R., Hill H., Blevins T.P., Yu Y., Zhang Y., et al. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. Vaccine 2013, 31:4874-4880.
154. Kong I.G., Sato A., Yuki Y., Nochi T., Takahashi H., Sawada S., et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun 2013, 81:1625-1634.
155. Lima F.A., Miyaji E.N., Quintilio W., Raw I., Ho P.L., Oliveira M.L. Pneumococcal surface protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice. Vaccine 2013, 31:2465-2470.
156. Perciani C.T., Barazzone G.C., Goulart C., Carvalho E., Cabrera-Crespo J., Gonçalves V.M., et al. Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response. Clin Vaccine Immunol 2013, 20:858-866.
157. Goulart C., da Silva T.R., Rodriguez D., Politano W.R., Leite L.C., Darrieux M. Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives. PLoS One 2013, 8:e59605.
158. Bologa M., Kamtchoua T., Hopfer R., Sheng X., Hicks B., Bixler G., et al. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine 2012, 30:7461-7468.
159. Chang L., Brooks W.A., de Bruyn G., Bologa M., Hopfer R., Kirby D., et al. A multi-component pneumococcal protein vaccine is safe and immunogenic in a phase 1 randomized, placebo-controlled study. Pneumonia 2014, 3:93-94.
160. Mann B., Thornton J., Heath R., Wade K.R., Tweten R.K., Gao G., et al. Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein. J Infect Dis 2014, 209:1116-1125.
161. Kamtchoua T., Bologa M., Hopfer R., Neveu D., Hu B., Sheng X., et al. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine 2013, 31:327-333.
162. Berglund J., Vink P., Tavares Da Silva F., Lestrate P., Boutriau D. Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults. Clin Vaccine Immunol 2014, 21:56-65.
163. Godfroid F., Hermand P., Verlant V., Denoël P., Poolman J.T. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2011, 79:238-245.
164. Leroux-Roels I., Devaster J.M., Leroux-Roels G., Verlant V., Henckaerts I., Moris P., et al. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials. Vaccine 2013;Oct 28, [Epub ahead of print].
165. Plumptre C.D., Ogunniyi A.D., Paton J.C. Vaccination against Streptococcus pneumoniae using truncated derivatives of polyhistidine triad protein D. PLoS One 2013, 8:e78916.
166. Browall S., Norman M., Tångrot J., Galanis I., Sjöström K., Dagerhamn J., et al. Intraclonal variations among Streptococcus pneumoniae isolates influence the likelihood of invasive disease in children. J Infect Dis 2014, 209:377-388.
167. Darrieux M., Moreno A.T., Ferreira D.M., Pimenta F.C., de Andrade A.L., Lopes A.P., et al. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J Med Microbiol 2008, 57:273-278.
168. Goulart C., Darrieux M., Rodriguez D., Pimenta F.C., Brandileone M.C., de Andrade A.L., et al. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine 2011, 29:1634-1642.
169. Liu Y., Wang H., Zhang S., Zeng L., Xu X., Wu K., et al. Mucosal immunization with recombinant fusion protein DnaJ-δA146Ply enhances cross-protective immunity against Streptococcus pneumoniae infection in mice via interleukin 17A. Infect Immun 2014, 82:1666-1675.
170. Ginsburg A.S., Nahm M.H., Khambaty F.M., Alderson M.R. Issues and challenges in the development of pneumococcal protein vaccines: a two day international symposium. Expert Rev Vaccines 2012, 11:279-285.
171. Figuera M., Moschioni M., De Angelis G., Barocchi M., Sabharwal V., Masignani V., et al. Variation of pneumococcal pilus-1 expression results in vaccine escape during experimental otitis media [EOM]. PLoS One 2014, 9:e83798.
172. Mizrachi Nebenzahi Y., Pornoi M., Kafka D., Shagan M., Blau K., Adawi A., et al. Identification of novel S. pneumoniae candidate vaccine antigens. 8th international symposium on pneumococci and pneumococcal diseases 2012, http://isppd.ekonnect.co/ISPPD_297/poster_22619/program.aspx.
173. Talukdar S., Zutshi S., Prashanth K.S., Saikia K.K., Kumar P. Identification of potential vaccine candidates against Streptococcus pneumoniae by reverse vaccinology approach. Appl Biochem Biotechnol 2014, 172:3026-3041.
174. Olaya-Abril A., Jiménez-Munguía I., Gómez-Gascón L., Obando I., Rodriguez-Ortega M.J. Identification of potential new protein vaccine candidates through pan-surfomic analysis of pneumococcal clinical isolates from adults. PLoS One 2013, 8:e70365.
175. Picard M.D., Cohane K.P., Gierahn T.M., Higgins D.E., Flechtner J.B. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge. Vaccine 2012, 30:4387-4393.
176. Hausdorff W, Godfroid F, Fierens F, Verlant V. Need for and development of a protein-based pneumococcal vaccine. http://www.meningitis.org.assets/x/53980.
177. Odutola A., Ota M.O., Antonio M., Ogundane O.E., Owiafe P., Worwui A., et al. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: phase II randomized study. Pneumonia 2014, 3:99-100.
178. Prymula R., Pazdiora P., Traskine M., Rüggeberg J.U., Borys D. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial. Vaccine 2014 Mar 31, [Epub ahead of print].
179. Leroux-Roels G., Maes C., De Boever F., Traskine M., Rüggeberg J.U., Borys D. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study. Vaccine 2014 Mar 6, [Epub ahead of print].
180. Pauksens K., Nilsson A.C., Caubet M., Pascal T.G., Van Belle P., Poolman J.T., et al. Randomized controlled study of pneumococcal vaccine formulations containing PhtD and dPly proteins with alum or adjuvant system AS02V in elderly adults: safety and immunogenicity. Clin Vaccine Immunol 2014 Mar 5, [Epub ahead of print].
181. Moffitt K.L., Yadav D.M., Anderson P.W., Malley R. Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine 2012, 30:4316-4322.
182. Gonçalves V.M., Dias W.O., Campos I.B., Liberman C., Sbrogio-Almeida M.E., Silva E.P., et al. Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability. Vaccine 2014, 32:1113-1120.
183. + T-cell dependent class switching and provides serotype independent protection against acute otitis media. EBMO Mol Med 2014, 6:141-154.
184. Ferreira D.M., Neill D.R., Bangert M., Gritzfeld J.F., Green N., Wright A.K.A., et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med 2013, 187:855-864.
185. Gonzalez B.E., Jacobs M.R. The potential of human nasal colonization with Streptococcus pneumoniae as a universal pneumococcal vaccine. Am J Respir Crit Care Med 2013, 187:794-795.